Glutamate oxaloacetate transaminase 1 is a cytoplasmic pyridoxal phosphate-dependent enzyme that catalyzes the reversible transamination between L-aspartate and α-ketoglutarate to form oxaloacetate and L-glutamate. It plays a central role in amino acid metabolism, the urea cycle, TCA cycle anaplerosis/cataplerosis via the malate-aspartate shuttle system for NADH transport into mitochondria. In cancer cells—especially those with KRAS mutations—GOT1 supports anabolic growth by maintaining NADPH/NADP+ balance critical for reactive oxygen species detoxification. Its upregulation is linked to tumor progression and poor prognosis; thus it is considered a promising target for anticancer drug development despite potential safety challenges due to its ubiquitous metabolic functions.
Drugs or inhibitors targeting GOT1 typically act by blocking its enzymatic activity, thereby disrupting the malate-aspartate shuttle, impairing redox homeostasis, and sensitizing cancer cells to metabolic stress such as glucose deprivation.
03
Biological functions
Amino acid metabolism (transamination between aspartate and glutamate)Urea cycle participationTricarboxylic acid (TCA) cycle involvementRegulation of cellular redox state and NADPH productionMalate-aspartate shuttle component for transferring reducing equivalents
04
Disease associations
Cancer (notably in KRAS-mutated cancers)Metabolic syndrome/obesity
05
Safety considerations
Potential safety concerns include disruption of normal amino acid metabolism and redox balance.Since GOT1 is involved in fundamental metabolic pathways across many tissues—including the brain—systemic inhibition could lead to off-target effects or toxicity related to impaired energy metabolism or neurotransmitter imbalance. These challenges are discussed when considering therapeutic targeting of this enzyme.
06
Interacting drugs
There are no widely approved drugs specifically targeting GOT1 in clinical use, but several experimental inhibitors are under investigation for cancer therapy. Examples include small-molecule GOT1 inhibitors used in preclinical studies.
07
Biomarkers
Elevated expression of GOT1 has been associated with poor prognosis in certain cancers such as lung adenocarcinoma, thyroid carcinoma, breast carcinoma, and metastatic melanoma; thus it may serve as a prognostic biomarker in these contexts.
Beyond the preview
Go deeper on Glutamate oxaloacetate transaminase 1 (GOT1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glutamate oxaloacetate transaminase 1 (GOT1).